Charles A. Deignan

2023

In 2023, Charles A. Deignan earned a total compensation of $854.4K as Chief Financial Officer at Clearside Biomedical, a 2% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$148,876
Option Awards$285,730
Salary$409,000
Other$10,800
Total$854,406

Deignan received $409K in salary, accounting for 48% of the total pay in 2023.

Deignan also received $148.9K in non-equity incentive plan, $285.7K in option awards and $10.8K in other compensation.

Rankings

In 2023, Charles A. Deignan's compensation ranked 1,384th out of 2,978 executives tracked by ExecPay. In other words, Deignan earned more than 53.5% of executives.

ClassificationRankingPercentile
All
1,384
out of 2,978
54th
Division
Manufacturing
824
out of 1,637
50th
Major group
Chemicals And Allied Products
541
out of 906
40th
Industry group
Drugs
528
out of 869
39th
Industry
Pharmaceutical Preparations
369
out of 627
41st
Source: SEC filing on April 26, 2024.

Deignan's colleagues

We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2023.

2023

George Lasezkay

Clearside Biomedical

Chief Executive Officer

2023

Thomas Ciulla

Clearside Biomedical

Chief Medical Officer

News

You may also like